

Potention of L-carnitine supplementation on changes in ejection fraction and left ventricular dimension in case of dilatative cardiomyopathy in children

by Wahyu Wibowo

Submission date: 20-Mar-2021 10:45AM (UTC+0800)

Submission ID: 1537524730

File name: r_dimension_in_case_of_dilatative_cardiomyopathy_in_children.pdf (296.42K)

Word count: 2967

Character count: 16038



Potention of L-carnitine supplementation on changes in ejection fraction and left ventricular dimension in case of dilatative cardiomyopathy in children

Wahyu Wibowo¹, Mahrus A Rahman^{1*}, I Ketut Alit Utamayasa¹

¹ Department of Child Health, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo Teaching Hospital, Surabaya Surabaya 60131, INDONESIA

*Corresponding author: mahrus_rahman@yahoo.com

Abstract

Background: Cardiomyopathy is a rare cardiac muscle disease with poor prognosis and high mortality. The main goal of dilated cardiomyopathy therapy is to restore and maximize cardiac function, but to date no medication has met these criteria. The use of oral L-carnitine as a dilated cardiomyopathy therapy has a potency to gives good results in restore and maximize cardiac function. **Purpose:** Knowing the effect of L-carnitine supplementation in children with cardiomyopathy on ejection fraction and left ventricular dimensions. **Method:** Experimental studies with randomized control trial design were conducted for one year, to determine the effect of L-carnitine in the experiment by performing twice the ejection fraction measurements and left ventricular dimensions performed before and after the administration of L-carnitine for 1 month. This research does not use blind method. Sampling was done randomly with comparison control. Different test was conducted with Saphiro-Wilk followed by T-test. **Result:** Fourteen samples were analyzed. In the treatment group, an increase in ejection fraction ($p = 0.033$), decreased left ventricular systolic phase end dimension ($p = 0.043$) and at the end of diastolic phase ($p = 0.170$). There was a significant difference in the increase of ejection fraction between treatment group and control group ($p = 0.035$), but no significant difference was found between treatment group and control group of final phase of systole ($p = 0.228$) and final phase of diastol ($p = 0.704$). **Conclusion:** L-carnitine supplementation in children with dilatative cardiomyopathy can increase ejection fraction, but not decrease the left ventricular dimension.

Keywords: dilated cardiomyopathy, L-carnitine, ejection fraction, left ventricular dimension

Wibowo W, Rahman MA, Utamayasa IKA (2020) Potention of L-carnitine supplementation on changes in ejection fraction and left ventricular dimension in case of dilatative cardiomyopathy in children. *Eurasia J Biosci* 14: 3475-3478.

© 2020 Wibowo et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License.

INTRODUCTION

Cardiomyopathy is a rare heart muscle disease with a poor prognosis and high mortality (Rong, et al. 2019). This heart muscle disease can affect blood flow throughout the body (Laswati, et al. 2018). Incidence varies between 2-8 cases every 100,000 to 17.2 cases per 100,000 population in all age groups. In most cases, no cause can be identified and the disease is considered idiopathic (Kaski, et al. 2010). About 40% of children with symptoms of cardiomyopathy need a transplant or will die within the first 2 years (Lipshultz, et al. 2003).

The main goal of dilatative cardiomyopathy therapy is to restore and maximize cardiac function, but until now there has been no drug that meets these criteria. Conventional therapies that are commonly used are diuretics, angiotension-converting enzymes / ACE inhibitors, and digoxin. This diuretic is only limited to reduce symptoms, ACE inhibitors such as in children are

still limited, digoxin does not reduce mortality and preferably use intravenous inotropic use in children (Abdullsattar Saad, 2007).

Levocarnitine (L-carnitine) is an essential amino acid derivative that has an important role in heart muscle metabolism. More than 90% are found in skeletal muscle cells and heart muscle cells. L-carnitine acts as a carrier of acyl co-enzyme A (CoA) needed in beta oxidation to produce energy for the heart muscle in the form of Adenosine Triphosphate (ATP) to carry out its activities. In dilatative cardiomyopathy there is an accumulation of toxic organic intermediates that are toxic in cells. This causes a reduction in the amount of L-carnitine (Helton, et al. 2000).

Received: May 2019

Accepted: April 2020

Printed: September 2020

8 **Table 1.** Difference between the initial and final ejection fraction in the treatment group (L-carnitine) and the initial and final ejection fraction in the control group

Variable	Early Average (SD)	End Average (SD)	p
Ejection Fraction			
Treatment	37,087 (14,553)	44,811 (17,981)	0,033
Control	44,627 (15,932)	44,197 (17,634)	0,837

6 8 **Table 2.** Differences between initial and final left ventricular dimensions in the treatment group (L-carnitine) and initial and final left ventricular dimensions in the control group

Variable	Early Average (SD) (cm)	Early Average (SD) (cm)	p
	Left Ventricular Dimension (<i>end sistole</i>)		
Treatment	4,624 (1,397)	4,140 (1,525)	0,043
Control	4,233 (1,405)	4,056 (1,624)	0,284
	Left Ventricular Dimension (<i>end diastole</i>)		
Treatment	5,589 (1,264)	5,294 (1,361)	0,170
Control	5,356 (1,229)	5,167 (1,005)	0,398

L-carnitine supplementation is expected to increase PI3K levels in the heart muscle so that it will improve contractility of the heart muscle and will also increase glucose metabolism and long-chain fatty acid metabolism which will ultimately increase the amount of energy in the form of ATP. Energy in the form of ATP will improve heart muscle metabolism so that contractility and elasticity will increase. With increasing contractility and elasticity of the heart muscle, there will be an increase in the ejection fraction and a decrease in the dimensions of the left ventricle. In addition to producing energy in the form of ATP, oxidation of this long chain fatty acids will also reduce the levels of these long chain fatty acids and reduce the levels of acyl-carnitine so that it will form protection in the form of membrane lipids and protein enzymes so that there is a potential restoring of rest of the heart muscle which will ultimately increase ejection fraction and decrease the dimensions of the left ventricle (Helton, et al. 2000; Tilahun, et al. 2015).

At the hospital Dr. Soetomo, Indonesia is still giving captopril, furosemide, and digoxin therapy to patients with dilatative cardiomyopathy. Evaluation of changes in ejection fraction and changes in left ventricular dimensions to assess the effect of L-carnitine supplementation by increasing contractility and elasticity of the heart muscle is expected to improve or improve the clinical condition of patients with dilatative cardiomyopathy.

METHOD

This type of research is experimental with a randomized control trial design research design, to determine the effect of treatment on the experiment by making two observations of variables that were made before and after treatment. This study did not use the blind method. The research lasted for 10 months.

Population and Sample

Sampling is done randomly with a comparison control. The subjects of this study were children aged 2-18 years who suffered from dilatative cardiomyopathy in the Outpatient and Pediatric Inpatient Care Department of Cardiology at Dr. Soetomo Hospital, Indonesia, who

met the inclusion and exclusion criteria. The study was divided into two groups. The first group (treatment) were children with conventional therapy plus L-carnitine supplementation 100 mg / kg / day and the second group were children with conventional (control) therapy. A total of 14 samples were examined for homogeneity in sex, age and weight.

Data analysis

The diagnosis of dilatative cardiomyopathy is determined based on the results of echocardiography performed and read by a child cardiology consultant Dr. Soetomo, Indonesia. The analysis used is descriptive analysis to determine the physical characteristics of the research subjects and independent sample T-Test to analyze differences in the ejection fraction and changes in the dimensions of the left ventricle as well as the difference in the ejection fraction and the difference in left ventricular dimension changes, the two groups (O1 and O1', O2 and O2'). Data were analyzed using 95% confidence level ($\alpha = 0.05$).

RESULTS

In this study the initial and final ejection fractions in the treatment group (L-carnitine) and the control group as shown in **Table 1**. From the data shown in **Table 1** it was found that there were significant differences between the initial and final ejection fractions in the treatment group (L-carnitine) whereas in the control group no significant differences were found. The value of each $p = 0.033$ for the value of the ejection fraction in the treatment group (L-carnitine) and $p = 0.373$ in the control group.

In this study the initial and final left ventricular dimensions in the treatment group (L-carnitine) and the control group as shown in **Table 2**.

From the data shown in **Table 3**, it was found that there was a significant difference / reduction in the left ventricular dimension of the late end systole (end systole) with the end of the treatment group (L-carnitine), but no significant difference / decrease in the left ventricular dimension of the final phase systole (end systole) beginning with end in the control group. But

Table 3. Difference in Changes in Ejection Fraction and Left Ventricular Dimensions in the Treatment Group (L-Carnitine) and in the Control Group

Deviation	Group		P
	Treatment	Control	
Ejection Fraction	7,724 ± 7,384	-0,430 ± 5,291	0,035
Left Ventricular Dimension:			
End systol (<i>end sistole</i>)	-0,484 ± 0,499	-0,177 ± 0,398	0,228
End diastol (<i>end diastole</i>)	-2,943 ± 0,500	-0,189 ± 0,516	0,704

there was no significant difference between the dimensions of the initial left ventricle (end diastole) with the end in each treatment group (L-carnitine) or in the control group. The value of $p = 0.043$ for the value of the dimensions of the left ventricle (end systole) and $p = 0.170$ for the value of the dimensions of the left ventricle (end diastole).

In this study the difference in changes in the ejection fraction and the dimensions of the left ventricle in the treatment group (L-carnitine) and the control group as shown in Table 3.

From the data shown in Table 3 it was found that there were significant differences between the ejection fraction differences in the treatment group (L-carnitine) compared to the control group with a p value = 0.035. But there was no significant difference in the difference between the dimensions of the left ventricular end systole (end systole) and at the end of diastole (end diastole) in each treatment group (L-carnitine) and the control group. The value of $p = 0.228$ for the value of the difference in the dimensions of the left ventricle at the end of systole (end systole) and $p = 0.704$ for the value of the dimension of the left ventricle at the end of diastole (end diastole).

In this study, there were no data on the incidence of intolerance in the form of diarrhea, nausea, vomiting and headaches as well as side effects in the form of fish odor after L-carnitine administration for 1 month.

DISCUSSION

In this study, there was a significant increase in ejection fraction after L-carnitine supplementation in the treatment group (L-carnitine), but in the control group there was no increase in ejection fraction. These results are in accordance with several studies that have been done before that look at the effect / effect of adding L-carnitine supplementation to the increase in ejection fraction.

Research on children with dilatative cardiopathy aimed at looking at the ejection fraction after administration of L-carnitine with a dose range of 14 - 455 mg / kg / day conducted for 2 weeks to 1 year and the results showed an increase in ejection fraction in the group given additional L-supplementation carnitine is significantly compared to the control group who received standard furosemide therapy, ACE inhibitors, digoxin, β blockers and Ca antagonists 6. Helton's study is different from this study in standard therapy and the

dose of L-carnitine used and the duration of L-carnitine administration.

In this study, there was a significant decrease in left ventricular dimension in the final phase of systole after L-carnitine supplementation for 1 month in the treatment group (L-carnitine), but there was no significant difference when comparing the difference / decrease in left ventricular dimension when systole between the treatment group with the control group. Different results obtained in the dimensions of the left ventricle in the final phase of diastole, ie no significant reduction was found in each treatment group (L-carnitine) and the control group. The difference in the decrease in left ventricular dimension when diastole between the treatment group and the control group was also not significant.

Previous studies in Egypt involving 14 children with dilatative cardiomyopathy looked at left ventricular function and serum L-carnitine levels between the treatment and control groups. The study was conducted for 3 months by giving additional L-carnitine to the treatment group at a dose of 100 mg / kg-weight / day. After 3 months of administration of L-carnitine, the result was a significant increase in the ejection fraction and a significant reduction in the left ventricular dimension of the final phase systole and the final phase of diastole. Kotby's research results are different from this study because the administration of L-carnitine is longer (3 months)(Abd, 2006)..

The oxidation of fatty acids by L-carnitine is the process that underlies the increased energy in the form of ATP in the heart muscle so that the contraction unit of the heart muscle increases (Ferrari, et al. 2004).L-carnitine also plays a role in increasing blood flow to the heart muscle that ischemia thereby preventing the accumulation of toxic metabolites (Morano, et al. 2007). Ischemia can occur in a variety of disease statuses and often occurs in various surgical procedures such as in the process of vascular surgery, although in children the risk level is lower than parents (Putri, & Hidajah, 2019. Lukiswanto, et al. 2017). From the results of an endomyocardial biopsy taken from the heart of a chronic heart failure patient, it is found that there is a relationship between decreased ATP concentrations with impaired contractions and relaxation (Ferrari, et al. 2004).

From the results of this study found a significant increase in the ejection fraction after administration of L-carnitine supplementation for 1 month in the treatment group compared to the control group. For the left ventricular dimension of the final systole phase there was no significant decrease after 1 month of L-carnitine supplementation in the treatment group compared to the control group, also the dimension of the left ventricle of the final phase of diastole was found to be insignificant reduction after L-carnitine supplementation for 1 month in the treatment group compared to the control group.

Researchers suspect that L-carnitine supplementation for 1 month in children with dilatative

cardiomyopathy has not been able to show an inhibitory effect on remodeling in heart muscle in children with dilatative cardiomyopathy. From previous studies stated that L-carnitine will show an inhibitory effect on remodeling of the heart muscle after being given for 2 to 12 months (Abd, 2006)

CONCLUSION

L-carnitine supplementation in children with dilatative cardiomyopathy can increase the ejection fraction, but does not decrease the left ventricular dimension.

REFERENCES

- Abd, A. M. N. E. D. (2006). Therapeutic Evaluation of L-Carnitine in Egyptian Children with Dilated Cardiomyopathy" Alyaa Amal Kotby," Gamal Abd El Nasser Yamamah," Abeer M. Nour El Din Abd El Baky," Ghada Mahmoud El Kassas and "Amal Zaghloul Abd Elhalim. *J. Med. Sci.* 6(5), 800-805.
- Abdullattar Saad, I. (2007). Idiopathic dilated cardiomyopathy in children; Natural history and predictors of prognosis. *Libyan Journal of Medicine*, 2(3), 129-134.
- Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., & Ceconi, C. (2004). Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: A review. *Annals of the New York Academy of Sciences*, 1033(1), 79-91
- Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., & Ceconi, C. (2004). Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: A review. *Annals of the New York Academy of Sciences*, 1033(1), 79-91.
- Helton, E., Darragh, R., Francis, P., Fricker, F. J., Jue, K., Koch, G.,... & Winter, S. C. (2000). Metabolic aspects of myocardial disease and a role for l-carnitine in the treatment of childhood cardiomyopathy. *Pediatrics*, 105(6), 1260-1270.
- Kaski, J. P., Syrris, P. M., Shaw, A. C., Esteban, M. T. T., McKenna, W. J., & Elliott, P. M. (2010). Mutations in the RAS/MAPK signalling pathway cause idiopathic hypertrophic cardiomyopathy in pre-adolescent children. OXFORD UNIV PRESS.
- Laswati, H., Sugiarto, D., Poerwandari, D., Pangkahila, J. A., & Kimura, H. (2018). Low-intensity exercise with blood flow restriction increases muscle strength without altering hsCRP and fibrinogen levels in healthy subjects. *Chin J Physiol*, 61(3), 188-195.
- Lipshultz, S. E., Sleeper, L. A., Towbin, J. A., Lowe, A. M., Orav, E. J., Cox, G. F.,... & Colan, S. D. (2003). The incidence of pediatric cardiomyopathy in two regions of the United States. *New England Journal of Medicine*, 348(17), 1647-1655.
- Lukiswanto, Ba. S., Wiwik misaco yuniarti YYM (2017). Effects of hyperbaric therapy on liver morphofunctional of rabbits (*Oryctolagus cuniculus*) after hind limb ischemia-reperfusion injury. *Vet World.*;10(11):1337–42.
- Morano, S., Mandosi, E., Fallarino, M., Gatti, A., Tiberti, C., Sensi, M.,... & Lenzi, A. (2007). Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. *European Urology*, 52(6), 1768-1776.
- Putri, A. P. S., & Hidajah, A. C. (2019). Indicator of Dyslipidemia for Ischemic Stroke in Elderly with Hypertension. *Indian Journal of Public Health Research & Development*, 10(3), 642-648.
- Rong, Sh.L, Wang, Z.K, Zhou BL, X. D (2019). Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis. *J Transl Med.* 17(1).
- Tilahun, G., Mekbib, F., Fikre, A., & Eshete, M. (2015). Genotype X Environment Interaction and Stability Analysis for Yield and Yield Related Traits of Desi-Type Chickpea (*Cicer Arietinum* L.) In Ethiopia. *Current Research in Agricultural Sciences*, 2(3), 100-113.

Potention of L-carnitine supplementation on changes in ejection fraction and left ventricular dimension in case of dilatative cardiomyopathy in children

ORIGINALITY REPORT

19%

SIMILARITY INDEX

5%

INTERNET SOURCES

17%

PUBLICATIONS

2%

STUDENT PAPERS

PRIMARY SOURCES

1

"Cardiovascular Medicine", Springer Science and Business Media LLC, 2007

Publication

2%

2

V. I. Popovych, I. V. Koshel, O. N. Malofiichuk, L. I. Pyletska, O. A. Semeniuk, O. V. Martynnyk, R. N. Orlovska, O. I. Leta. "Multicenter, Randomized, Open-Label, Comparative Study of Therapeutic Efficacy, Safety and Tolerability of BNO 1030 application in the technology of delayed prescription of antibiotics in patients with severe acute tonsillitis", Cold Spring Harbor Laboratory, 2021

Publication

2%

3

Submitted to Universitas Airlangga

Student Paper

2%

4

Astrid M. De Souza. "A stress echocardiography study of cardiac function during progressive exercise in pediatric oncology patients treated with anthracyclines", Pediatric Blood & Cancer,

2%

5

Nasir Talenezhad, Mohammad Mohammadi, Nahid Ramezani-Jolfaie, Hassan Mozaffari-Khosravi, Amin Salehi-Abargouei. "Effects of L-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis", *Clinical Nutrition ESPEN*, 2020

Publication

1%

6

Alyaa Amal Kotby ., Gamal Abd El Nasser ., Abeer M. Nour El Din ., Ghada Mahmoud El Kas ., Amal Zaghloul Abd El .. "Therapeutic Evaluation of L-Carnitine in Egyptian Children with Dilated Cardiomyopathy", *Journal of Medical Sciences*, 2006

Publication

1%

7

repository.unair.ac.id

Internet Source

1%

8

G.Michael Felker, Joshua M. Hare, Kenneth L. Baughman, Edward K. Kasper. "Transplant-free survival in infiltrative diseases of the myocardium", *Journal of Cardiac Failure*, 1999

Publication

1%

9

Bambang Sektiari Lukiswanto, Wiwik Misaco Yuniarti, Y. Yosis Motulo. "Effects of hyperbaric

1%

therapy on liver morphofunctional of rabbits (Oryctolagus cuniculus) after hind limb ischemia-reperfusion injury", Veterinary World, 2017

Publication

10

Masako Kuwasawa-Iwasaki, Hiroaki Ito, Masahiro Muto, Saki Ichikawa et al. "Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis", Nutrients, 2020

1%

Publication

11

"1-A7: Environmental & Occupational Health and Epidemiology : Poster Sessions", Respirology, 2013.

1%

Publication

12

Brook Belay, Nora Esteban-Cruciani, Christine A. Walsh, Frederick J. Kaskel. "The use of levocarnitine in children with renal disease: a review and a call for future studies", Pediatric Nephrology, 2005

<1%

Publication

13

Edgars Liepinsh, Ivars Kalvinsh, Maija Dambrov. "Chapter 6 The Regulation of Energy Metabolism Pathways Through L-Carnitine Homeostasis", IntechOpen, 2011

<1%

Publication

14

www.ekolojidergisi.com

<1%

15

A. Chaudhuri. "Patient education to encourage graded exercise in chronic fatigue syndrome", *BMJ*, 6/23/2001

Publication

<1%

16

P.P. Steele. "Advantages of list-mode acquisition of high resolution dynamic cardiac data", 1996 IEEE Nuclear Science Symposium Conference Record, 1996

Publication

<1%

17

Bo Wu. "Dan Shen agents for acute ischaemic stroke", *Cochrane Database of Systematic Reviews*, 04/18/2007

Publication

<1%

18

Gilson C. Fernandes, Leonardo Knijnik, Juan Lopez, Manuel Rivera et al. "Network Meta-analysis of His Bundle, Biventricular or Right Ventricular Pacing as a Primary Strategy for Advanced Atrioventricular Conduction Disease with Normal or Mildly Reduced Ejection Fraction", *Journal of Cardiovascular Electrophysiology*, 2020

Publication

<1%

19

Marta Reyes-Corral, Noelia Sola-Idígora, Rocío de la Puerta, Joan Montaner, Patricia Ybot-González. "Nutraceuticals in the Prevention of

<1%

Neonatal Hypoxia–Ischemia: A Comprehensive Review of their Neuroprotective Properties, Mechanisms of Action and Future Directions", International Journal of Molecular Sciences, 2021

Publication

20

Renata Silvério. "l-carnitine and cancer cachexia: Clinical and experimental aspects", Journal of Cachexia Sarcopenia and Muscle, 01/26/2011

Publication

21

Wei-Kai Wu, Suraphan Panyod, Po-Yu Liu, Chieh-Chang Chen et al. "Characterization of TMAO productivity from carnitine challenge facilitates personalized nutrition and microbiome signatures discovery", Microbiome, 2020

Publication

22

scialert.net

Internet Source

23

McKee, James R & McKee, Trudy. "Biochemistry- The Molecular Basis of Life", Oxford University Press, 2020

Publication

24

Panagiotis C. Voukydis. "The effect of distension of the left ventricle of the heart on the length of the individual myocardial fibers", The Bulletin of Mathematical Biophysics, 1970

<1%

<1%

<1%

<1%

<1%

25

Tom L Broderick, Jenny Cifuentes, Denise Green, Dennis J Paulson. "Short-term carnitine deficiency does not alter aerobic rat heart function but depresses reperfusion recovery after ischemia", Canadian Journal of Physiology and Pharmacology, 2001

<1%

Publication

Exclude quotes On

Exclude matches Off

Exclude bibliography On

Potention of L-carnitine supplementation on changes in ejection fraction and left ventricular dimension in case of dilatative cardiomyopathy in children

GRADEMARK REPORT

FINAL GRADE

/100

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4
